Geneva Capital Management LLC Purchases 2,241 Shares of STAAR Surgical (NASDAQ:STAA)

Geneva Capital Management LLC lifted its position in shares of STAAR Surgical (NASDAQ:STAA) by 0.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 695,415 shares of the medical instruments supplier’s stock after purchasing an additional 2,241 shares during the quarter. Geneva Capital Management LLC owned about 1.41% of STAAR Surgical worth $25,835,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in STAA. Victory Capital Management Inc. boosted its holdings in shares of STAAR Surgical by 16.7% during the 3rd quarter. Victory Capital Management Inc. now owns 189,481 shares of the medical instruments supplier’s stock valued at $7,039,000 after buying an additional 27,143 shares in the last quarter. Aigen Investment Management LP bought a new stake in STAAR Surgical during the third quarter worth about $293,000. GSA Capital Partners LLP grew its holdings in STAAR Surgical by 134.8% in the third quarter. GSA Capital Partners LLP now owns 118,789 shares of the medical instruments supplier’s stock worth $4,413,000 after purchasing an additional 68,196 shares during the period. Versor Investments LP grew its holdings in STAAR Surgical by 98.6% in the third quarter. Versor Investments LP now owns 16,400 shares of the medical instruments supplier’s stock worth $609,000 after purchasing an additional 8,142 shares during the period. Finally, Los Angeles Capital Management LLC lifted its holdings in shares of STAAR Surgical by 78.3% during the third quarter. Los Angeles Capital Management LLC now owns 16,474 shares of the medical instruments supplier’s stock valued at $612,000 after purchasing an additional 7,237 shares during the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Price Performance

Shares of STAAR Surgical stock opened at $29.02 on Wednesday. The stock has a market capitalization of $1.43 billion, a PE ratio of 65.95 and a beta of 0.61. STAAR Surgical has a 1-year low of $26.66 and a 1-year high of $52.68. The company’s fifty day simple moving average is $31.52 and its 200-day simple moving average is $37.62.

Analysts Set New Price Targets

Several research firms have commented on STAA. Stifel Nicolaus dropped their target price on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, August 26th. Canaccord Genuity Group lowered their price target on STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 1st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, STAAR Surgical presently has an average rating of “Hold” and an average price target of $43.33.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.